
“Pharma Bro” Martin Shkreli filed motions in May to dismiss the Federal Trade Commission’s (FTC) claims that his company Vyera Pharmaceuticals boxed out competition and created a monopoly for the toxoplasmosis drug Daraprim after raising prices by 4,000% overnight. But on Tuesday, August 18, a federal judge said not so fast.
Judge Denise Cote denied all but one request for dismissal. The suit was filed in January by the Federal Trade Commission, New York, and other states, which claimed that Shkreli and co-defendant Kevin Mulleady participated in “an unlawful scheme” to hinder generic competition and “preserve a monopoly,” which they allegedly kept going even while Shkreli was in prison, according to court documents.
Shkreli and Mulleady launched Vyera in 2014, then known as Turing Pharmaceuticals, and snagged US rights to Daraprim for US$55 million the following year. Overnight, the company raised Daraprim’s price from US$17.50 to US$750 per tablet. The move was a familiar one for Shkreli, whose company Retrophin acquired the rights to Thiola in 2014, then raised its price by 2,000%, according to the FTC complaint.
Full Content: ENDPOINTS News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ Antitrust Chief Gail Slater Assembles Veteran Team for Key Cases
Mar 16, 2025 by
CPI
UK Demands Access to Apple’s Encrypted Cloud Data, Spark Legal and Privacy Battle
Mar 16, 2025 by
CPI
Turkey Probes Netflix, Disney+, and Amazon Over Anti-Competitive Practices
Mar 16, 2025 by
CPI
Elon Musk and OpenAI Agree to Accelerate Trial Amidst Legal Battle Over AI’s For-Profit Shift
Mar 16, 2025 by
CPI
AI in Markets: A Double-Edged Sword for Competition, Says CCI Chief
Mar 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li